Compare Johnson & Johnson (JNJ) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Oatly Group AB - ADR — how do they compare? Johnson & Johnson trades at $260.5 (market cap $618.09B), while Oatly Group AB - ADR trades at $10.46 (market cap $330.93M). The key difference: Johnson & Johnson is far larger — about 1867.7× Oatly Group AB - ADR's market cap, and Johnson & Johnson pays a 2.09% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Oatly Group AB - ADR for 18 Days on average.
| JNJ | OTLY | |
|---|---|---|
Market Cap | $618.09B | $330.93M |
Volume | 6,050,983 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $15.91 |
52-Week Low | $186.00 | $8.03 |
Typical Hold Time | 129 Days | 18 Days |
Enterprise Value | $646.37B | $835.34M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Oatly (OTLY) trades at $10.42, up 0.48% on the day, amid mixed technical signals and ongoing fundamental challenges. The stock shows a bearish moving average trend but bullish oscillators, with key support at $10. Revenue growth is steady, reaching $862.46M in 2025, yet profitability remains elusive with a net income margin of -13.81%. Recent Q2 2026 results beat expectations, and management raised full-year revenue guidance, driving positive sentiment from some analysts.
The outlook is cautiously optimistic, with a consensus price target of $12.28 suggesting 18% upside, but significant risks persist. High debt levels, negative cash flows, and intense competition in the plant-based food sector threaten near-term stability. Investors should weigh the potential for operational turnaround against persistent losses and leverage concerns before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
